Finance

Lists
Why is ZVRA up 3,55%?
Dive Deeper
ZVRA:NASDAQ
Zevra Therapeutics Inc
11,39 USD
+3,55%
(+0,39) 1D
11,39 USD
0,00% (0,00)
After hours
Closed: 9-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZVRA...
Open
10,95 USD
High
11,46 USD
Low
10,95 USD
Mkt. cap
676,38 млн
Avg. vol.
953,47 миң
Volume
730,74 миң
P/E ratio
11,89
52-wk high
15,04 USD
52-wk low
8,01 USD
EPS
0,96 USD
Beta
0,98
Shares outstanding
59,38 млн
No. of employees
61
Open
10,95 USD
High
11,46 USD
Low
10,95 USD
Mkt. cap
676,38 млн
Avg. vol.
953,47 миң
Volume
730,74 миң
P/E ratio
11,89
52-wk high
15,04 USD
52-wk low
8,01 USD
EPS
0,96 USD
Beta
0,98
Shares outstanding
59,38 млн
No. of employees
61
News stories
From web sources and news partners
About Zevra Therapeutics Inc
CEO-
Employees61
Founded2006
Headquarters-
SectorPharmaceutical industry
Websitezevra.com
Analyst ratings
Based on 9 analysts giving stock ratings to ZVRA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ZVRA in the last 3 months.
Highest
Current 11,39 USD
35,00 USD (+207,29%)
Average
25,25 USD (+121,69%)
Lowest
20,00 USD (+75,59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/30/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
26,00 USD
+128,3%
09/21/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
20,00 USD
+75,6%
08/11/2026
Jason McCarthy
Maxim Group
Buy
Maintained
35,00 USD
+207,3%
08/06/2026
Eddie Hickman
Guggenheim
Buy
Maintained
23,00 USD
+101,9%
08/06/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
21,00 USD
+84,4%
08/06/2026
Kambiz Yazdi
BTIG
Buy
Maintained
24,00 USD
+110,7%
08/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
28,00 USD
+145,8%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
25,00 USD
+119,5%
08/05/2026
Unknown Analyst
Roth MKM
Buy
Maintained
21,00 USD
+84,4%
05/07/2026
Last report
2026-ж., 5-авг.
Fiscal period
Q2 2026
0,25 USD / 0,18 USD
+41,51%beat
Revenue / Est. (USD)
39,66 млн / 34,84 млн
+13,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
26,06 млн
34,12 млн
36,22 млн
39,66 млн
Cost of goods sold
1,24 млн
1,52 млн
1,90 млн
1,52 млн
Cost of revenue
1,24 млн
1,52 млн
1,90 млн
1,52 млн
Research and development expenses
3,43 млн
2,52 млн
4,39 млн
4,49 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,94 млн
20,45 млн
20,78 млн
16,56 млн
Operating expense
20,68 млн
23,29 млн
25,49 млн
21,36 млн
Total operating expenses
21,92 млн
24,81 млн
27,39 млн
22,89 млн
Operating income
4,14 млн
9,32 млн
8,83 млн
16,78 млн
Other non operating income
-5,51 млн
3,56 млн
-6,25 млн
-6,41 млн
EBT including unusual items
-977,00 миң
12,67 млн
44,80 млн
12,79 млн
EBT excluding unusual items
-1,10 млн
12,64 млн
4,46 млн
12,93 млн
Income tax expense
-433,00 миң
501,00 миң
6,91 млн
4,04 млн
Effective tax rate
44,32%
3,96%
15,43%
31,59%
Other operating expenses
-
-
-
-
Net income
-544,00 миң
12,16 млн
37,89 млн
8,75 млн
Net profit margin
-2,09%
35,65%
104,61%
22,07%
Earnings per share
-0,01
0,19
0,18
0,25
Interest and investment income
2,31 млн
1,71 млн
3,59 млн
2,56 млн
Interest expense
-2,05 млн
-1,95 млн
-1,71 млн
-
Net interest expenses
262,00 миң
-236,00 миң
1,88 млн
2,56 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,54 млн
9,68 млн
9,20 млн
17,14 млн
Gain or loss from assets sale
-
63,00 миң
-43,31 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору